Fig. 1

Kaplan-Meier survival estimates in patients from the INNSBRUCK set (a, b) and from the GRONINGEN set (c, d) who received carboplatin-based chemotherapy (a, c) and in patients who received no carboplatin-based chemotherapy (b, d) according to the presence or the absence of HOTAIR RNA in their ovarian cancer tumour specimens. The survival analysis was performed in the INNSBRUCK set based on the patients who did receive carboplatin-based chemotherapy (n = 63) referred to as “Carboplatin Therapy” and the 71 ovarian cancer patients who received cisplatin-based (n = 55) or no chemotherapy (n = 16) referred to as “No Carboplatin Therapy”. In the GRONINGEN set the survival analysis was performed based on the ovarian cancer patients who did receive carboplatin-based chemotherapy (n = 157), referred to as “Carboplatin Therapy” and patients who received cisplatin-based chemotherapy (n = 18), referred to as “No Carboplatin Therapy”. n.s not significant, OS overall survival